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Rationale: Identification of risk factors for lung cancer can help in selecting patients who may
benefit the most from smoking cessation interventions, early detection, or chemoprevention.
Objective: To evaluate whether the presence of emphysema on low-radiation-dose CT (LDCT) of
the chest is an independent risk factor for lung cancer.
Methods: The study used data from a prospective cohort of 1,166 former and current smokers
participating in a lung cancer screening study. All individuals underwent a baseline LDCT and
spirometry followed by yearly repeat LDCT studies. The incidence density of lung cancer among
patients with and without emphysema on LDCT was estimated. Stratified and multiple regression
analyses were used to assess whether emphysema is an independent risk factor for lung cancer
after adjusting for age, gender, smoking history, and the presence of airway obstruction on
spirometry.
Results: On univariate analysis, the incidence density of lung cancer among individuals with and
without emphysema on LDCT was 25.0 per 1,000 person-years and 7.5 per 1,000 person-years,
respectively (risk ratio [RR], 3.33; 95% confidence interval [CI], 1.41 to 7.85). Emphysema was
also associated with increased risk of lung cancer when the analysis was limited to individuals
without airway obstruction on spirometry (RR, 4.33; 95% CI, 1.04 to 18.16). Multivariate analysis
showed that the presence of emphysema (RR, 2.51; 95% CI, 1.01 to 6.23) on LDCT but not airway
obstruction (RR, 2.10; 95% CI, 0.79 to 5.58) was associated with increased risk of lung cancer
after adjusting for potential cofounders.
Conclusions: Results suggest that the presence of emphysema on LDCT is an independent risk
factor for lung cancer. (CHEST 2007; 132:1932–1938)
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L ung cancer is the deadliest malignancy in theworld among men and women.1,2 Major public
health efforts have focused on developing new inter-
ventions to decrease smoking rates, the main risk
factor for lung cancer, and to test for strategies that
could lead to early detection or effective chemopre-
vention. In particular, lung cancer screening using
low-radiation-dose CT (LDCT) is a promising strat-
egy currently undergoing intensive research efforts.
An important aspect of these strategies is the
ability to identify patients at high risk for lung
cancer who may benefit the most from smoking
cessation treatments, early diagnosis, or chemo-
prevention. Moreover, several studies3 have shown
that the cost-effectiveness of these interventions is
highly dependent on the prevalence of lung cancer
in the target population.
COPD, also strongly associated with cigarette
smoking, is a highly prevalent condition that in
industrialized countries is only second to heart dis-
ease as a cause of death.3 Most patients with COPD
have a combination of chronic bronchitis and em-
physema, which is anatomically defined as an abnor-
mal permanent enlargement of the airspaces distal to
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the terminal bronchioles, accompanied by destruc-
tion of their walls without obvious fibrosis.4 Accord-
ing to international guidelines, the diagnosis of
COPD requires the presence of airway obstruction
on spirometry.5 In recent years, CT has been shown
to accurately identify areas of the lung parenchyma
involved with emphysema.5,6 CT may be more sen-
sitive than pulmonary function tests for the detection
of emphysema, but the clinical significance of em-
physema diagnosed on CT in the absence of airway
obstruction is not yet clear.
It has been shown that patients with COPD,
defined by the presence of airway obstruction, are at
increased risk for lung cancer.7 However, there are
limited data regarding the potential association be-
tween emphysema diagnosed on chest CT and lung
cancer, particularly among individuals with normal
airway function. In this study, we used data from an
unselected population of current and former smok-
ers participating in a lung cancer screening study to
assess whether emphysema detected on LDCT is an
independent risk factor for lung cancer.
Materials and Methods
The study was conducted using data from a prospective cohort
of individuals enrolled in a lung cancer screening study using
LDCT from September 2000 to December 2005.8 Eligibility
criteria included age 40 years, 10 pack-year smoking history,
and no symptoms of lung cancer. The study protocol consisted of
a baseline LDCT of the chest followed by annual repeat studies
for up to 5 years. All patients underwent spirometry at enrollment
and a baseline standardized questionnaire to collect sociodemo-
graphic information and smoking history data. The ethics com-
mittee of the University of Navarra approved the study protocol,
and all subjects signed an informed consent form prior to
participation.
LDCT
LDCT examinations were performed in a single breath-hold at
end-inspiration. The initial 297 subjects were studied with a
single-slice helical scanner (Somatom Plus 4; Siemens; Erlangen,
Germany) at low-dose settings (140 kilovolt peak, 43 mA seconds)
and 1.5 pitch with a collimation of 8 mm. We used a four-row
multislice helical CT scanner (Somatom Volume Zoom; Siemens;
Forchheim, Germany) also at a low-dose setting (120 kilovolt
peak, 20 mA seconds, and 1.25-mm slice thickness) for all
subsequent studies. All images were reconstructed using a high-
spatial-frequency algorithm and displayed at window settings
appropriate for viewing the lung parenchyma (window width of
1,500 Hounsfield units, and window center of  650 Hounsfield
units).9
Assessment of Emphysema on LDCT
All images were read by two expert chest radiologists for
visual assessment of the presence of emphysema, using vali-
dated criteria.6 In brief, the extent of emphysema was graded
from 0 to 4, with a grade of 0 indicating no emphysema, and
a grade of 4 indicating the presence of emphysema in  75%
of the lung.6 For the purpose of this study, patients with a
score  1 were classified as having emphysema.
Spirometry
Airway function was measured at baseline in all study partici-
pants using a flow spirometer (V˙max 22; SensorMedics; Yorba
Linda, CA) according to the standards of the American Thoracic
Society.4 FEV1 and FVC measures were expressed as a percent-
age of the predicted value according to the European Commu-
nity Lung Health Survey.10 Using the criteria established by the
Global Initiative for Chronic Obstructive Lung Disease, subjects
with a FEV1/FVC ratio  70% were classified as having airway
obstruction.5
Lung Cancer Diagnostic Algorithm
Study participants were evaluated for the presence of lung
cancer using a standardized diagnostic algorithm.11 Briefly, pa-
tients with noncalcified nodules  10 mm were followed up with
repeat LDCTs and further workup if growth of a nodule was
detected. Subjects with suspicious nodules 10 mm were immedi-
ately referred for positron emission tomography, percutaneous
needle biopsy, or intraoperative biopsy. For the purpose of the
study, all cases of lung cancer diagnosed as a consequence of
screening or due to a new onset of symptoms (interval cases) were
included in the analysis.
Data Analysis
Normal data are presented as mean SD, and nonnormal
variables are presented as median (interquartile range [IQR]).
The agreement between raters for the visual assessment of
emphysema and the  coefficient for interrater reliability was
calculated.12,13
The incidence density of lung cancer was calculated with
person-years as the denominator under the Poisson assumption.14
We used the risk ratio (RR) with 95% confidence intervals (CIs)
to compare the risk of lung cancer among study subjects with and
without emphysema.
Stratified analyses were also conducted to evaluate the rela-
tionship between emphysema and lung cancer risk among pa-
tients with normal airway function. We used Poisson regression
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to assess whether emphysema on LDCT was independently
associated with lung cancer incidence density after controlling for
other known risk factors such as age, gender, presence of airway
obstruction, and smoking history (number of pack-years). All
analyses were performed with statistical software (version 9.0;
SAS Institute; Cary, NC) and using two-sided p values.
Results
A total of 1,166 individuals were included in the
study. Baseline characteristics of the study partici-
pants are shown in Table 1. All participants were
white western Europeans, mean age was 54 8 years,
and 74%were male. The median number of pack-years
smoked was 33 (IQR: 22 pack-years). Overall, 29%
(95%CI, 26 to 31%) of the subjects had emphysema on
baseline LDCT and 25% (95% CI, 22 to 27%) had
airway obstruction on spirometry (Fig 1). Fifty-three
percent of the participants with emphysema on CT had
no airway obstruction. The interrater agreement for the
presence or absence of emphysema based on visual
assessment was excellent ( coefficient 0.91).
Lung cancer was diagnosed in 23 participants. Sev-
enteen cases were detected on baseline screening, and
6 cases were detected on annual repeat screening. No
interval lung cancers were diagnosed. Adenocarcinoma
was the most frequent histologic type (57%), followed
by squamous cell carcinoma (22%), small cell carci-
noma (17%), and large cell carcinoma (4%). Nearly
80% of the cancers were diagnosed in stage I, 13% in
stage II, and 7% in stage III.
Relationship Between Emphysema Distribution,
Cancer Location, and Histologic Type
Of the 17 individuals with lung cancer and emphy-
sema on LDCT, 16 patients (94%) had heterogenous
emphysema with upper-lobe predominance and the
cancer was located in the upper lobes. One individ-
ual had homogenous emphysema and lung cancer in
the left lower lobe. The histologic type of cancer in
10 of the 17 individuals with emphysema (58%) was
adenocarcinoma.
Table 1—Baseline Characteristics of Study
Participants*
Characteristics Data
Age, yr 54  8
Male gender, % 74
Smoking history, median pack-yr 33 (IQR: 22)
Spirometry results, % predicted
FEV1 95  18
FVC 105 16
FEV1/FVC ratio 75  8
Airway obstruction, %† 25
LDCT result
Emphysema, %‡ 29
*Data are presented as mean  SD unless otherwise indicated.
†Percentage of participants with FEV1/FVC  70% of predicted.
‡Percentage of participants with emphysema on LDCT grade 1 or
more.
Figure 1. Distribution of participants with lung cancer according to the presence or absence of airway
obstruction (AO) and/or emphysema (E).
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Relationship Between Emphysema and the Risk of
Lung Cancer
On univariate analysis, the incidence density of
lung cancer among individuals with and without
emphysema on LDCT was 25.0 per 1,000 person-
years and 7.5 per 1,000 person-years, respectively
(RR, 3.33; 95% CI, 1.41 to 7.85; Table 2). Similarly,
the incidence density of lung cancer in individuals
with and without airway obstruction on spirometry
was 32.3 per 1,000 person-years and 6.7 per 1,000
person-years, respectively (RR, 4.83; 95% CI, 2.05
to 11.41).
A potential synergy between emphysema detected
on LDCT and airway obstruction detected on spi-
rometry is suggested by the increased incidence
density of lung cancer in subjects with both condi-
tions (37.5 per 1,000 person-years) as compared to
those with neither one (3.4 per 1,000 person-years;
RR, 5.49; 95% CI, 1.51 to 19.98). The incidence
density of lung cancer in subjects with only one of
the two abnormalities (emphysema or airway obstruc-
tion) was 18.8 per 1,000 person-years (RR, 10.94; 95%
CI, 3.01 to 39.74; Table 2).
In the stratified analysis, the presence of emphy-
sema on LDCT was associated with an increased
likelihood of a lung cancer diagnosis among subjects
without airway obstruction (RR, 4.33; 95% CI, 1.04
to 18.16). When the analysis was limited to partici-
pants with airway obstruction on spirometry, no
relationship between emphysema on LDCT and
lung cancer risk was found (RR, 1.48; 95% CI, 0.51
to 4.34).
The results of the Poisson regression analyses are
shown in Table 3. Emphysema detected on LDCT
was significantly associated with a higher risk of lung
cancer in a model adjusting for age, gender, and
number of pack-years of smoking (RR, 3.13; 95% CI,
1.32 to 7.44; model 1). Lung cancer was also more
common among patients with airway obstruction
after controlling for the same covariates (RR, 2.89;
95% CI, 1.14 to 7.27; model 2). However, in a final
model (model 3) that included terms for presence of
emphysema, airway obstruction, age, gender, and
smoking history, emphysema (RR, 2.51; 95% CI,
1.01 to 6.23) and the number of pack-years of
smoking (RR, 2.9; 95% CI, 1.1 to 7.2) but not airway
obstruction (RR, 2.10; 95% CI, 0.79 to 5.58) were
independently associated with a higher risk for lung
cancer.
Discussion
Results of this prospective cohort study of current
and former smokers suggest that the presence of
Table 2—Unadjusted and Stratified Association Between Emphysema, Airway Obstruction, and Incidence of
Lung Cancer
Risk Factors
No. of Lung
Cancers
Person-Years
of Follow-up
Incidence Density
(per 1,000 Person-Years) RR (95% CI)
Univariate analysis
No emphysema 8 1,065 7.5 Reference
Emphysema 15 600 25.0 3.33 (1.41–7.85)
No airway obstruction 8 1,200 6.7 Reference
Airway obstruction 15 465 32.3 4.83 (2.05–11.41)
No emphysema, no airway obstruction 3 876 3.4 Reference
Emphysema or airway obstruction 10 531 18.8 5.50 (1.51–19.99)
Emphysema and airway obstruction 10 267 37.5 10.94 (3.01–39.74)
Stratified analysis
No airway obstruction
No emphysema 3 876 3.5 Reference
Emphysema 5 333 15.0 4.33 (1.04–18.16)
Airway obstruction
No emphysema 5 198 2.5 Reference
Emphysema 10 267 3.8 1.48 (0.51–4.34)
Table 3—Results of Multivariate Analysis*
Risk Factors RR 95% CI
Model 1
Emphysema 3.13 1.32–7.44
No emphysema Reference
Model 2
Airway obstruction 2.89 1.14–7.27
No airway obstruction Reference
Model 3
Emphysema 2.51 1.01–6.23
No emphysema Reference
Airway obstruction 2.10 0.79–5.58
No airway obstruction Reference
*All models were adjusted for age, gender, and No. of pack-years of
smoking. Pack-years of smoking was significantly associated with an
increased risk of lung cancer in all three models.
www.chestjournal.org CHEST / 132 / 6 / DECEMBER, 2007 1935
 © 2007 American College of Chest Physicians
 at Navarra University on June 27, 2012chestjournal.chestpubs.orgDownloaded from 
emphysema on LDCT is associated with an increased
risk for lung cancer. Stratified and multivariate analyses
showed that this association was significant even after
controlling for the presence of airway obstruction on
spirometry, suggesting that emphysema on LDCT is an
independent risk factor for lung cancer. This informa-
tion can help identify patients at high risk for lung
cancer who may benefit from more-aggressive preven-
tive interventions or lung cancer screening programs.
The majority of lung cancers occur in current or
former smokers, and the risk increases with older age
and longer exposure to tobacco.3 However, lung cancer
develops in only a minority of smokers. Therefore, the
identification of additional factors that may help in the
selection of individuals with the highest risk may be
useful. Many reports7 have linked abnormal airway
function on pulmonary function testing with an in-
creased risk for lung cancer. There is less information
regarding the association between emphysema and
lung cancer.15–17
Emphysema has traditionally been a pathologic
diagnosis, but the development of CT-based image
analysis techniques has lead to accurate noninvasive
in vivo detection and quantification of emphysema.18
For example, CT has been shown to be useful in the
selection of individuals with severe emphysema who
are at a greater risk for a poor outcome after lung
volume reduction surgery (ie, those with a homog-
enous distribution of emphysema).6 Moreover,
quantification of emphysema using CT has been
used to follow the effects of replacement therapy
in patients with 1-antitrypsin deficiency.19,20 However,
the clinical significance of emphysema on CT among
individuals without symptoms or with normal pulmo-
nary function tests remains unclear. A novelty of this
study is the use of LDCT instead of high-resolution
CT, as has been used in the aforementioned studies.
In this study, a strong association between emphy-
sema detected on LDCT and lung cancer risk was
found even among individuals with normal airway
function. These results are consistent with previous
retrospective and epidemiologic reports.15–17,21 Ad-
ditionally, a recent study22 has found that emphy-
sema detected on CT, and not airway obstruction,
was associated with a worse prognosis in smokers with
early stage lung cancer. Conversely, a case-controlled
study23 using data from subjects enrolled in the Mayo
Clinic LDCT early lung cancer detection study found
that severe airway obstruction, but not emphysema,
was associated with a higher risk of lung cancer. The
discrepancy in the results between this study and ours
may be explained by several reasons. Firstly, the Mayo
Clinic study follows a case-control design in which only
a small subgroup of individuals of the entire cohort is
used in the analysis. In our study, the entire population
entered into the lung cancer screening trial was in-
cluded in the analysis. Secondly, the proportion of
subjects with airway obstruction that were included in
the analysis was 67% and 79% in the control and lung
cancer groups, respectively, in the Mayo Clinic study,
and 25% in ours. Lastly, the method to determine the
presence of emphysema was quantitative in the Mayo
Clinic study and by visual assessment in ours. In the
former, participants were subclassified into groups
depending on the amount of emphysema; whereas in
our study, only the presence or absence of emphysema
was considered for the analysis.
The findings presented herein have several poten-
tial clinical implications. Lung cancer is the most
lethal cancer in the world mainly due to the fact that
 80% of cases are diagnosed in advanced stages of
the disease. In the last few years, a great interest in
lung cancer screening research has emerged. A
recent report by the International Early Lung Can-
cer Action Program consortium,11 among other stud-
ies, has shown promising results using annual LDCT.
Other studies24 have found different results raising
questions about mortality benefit, cost-effectiveness,
and safety of lung cancer screening using LDCT.
Several randomized control studies in the United
States and in Europe are underway, and results
should be available in a few years. If early detection
of lung cancer with LDCT is shown to be effective
by studies currently underway, the appropriate se-
lection of the target population will be very impor-
tant. For a screening program to be beneficial and
cost-effective, it is necessary to identify individuals
with the highest risk for lung cancer so that there is
an adequate ratio of prevalence of the disease to the
number of false-positive findings. The results pre-
sented herein suggest that emphysema detected on a
baseline LDCT could be used in this context to
identify individuals who may need additional follow-
up studies. Conversely, individuals with no evidence of
emphysema and with no suspicious nodules on a
baseline LDCT may not require further screening.
Additionally, LDCT screeningmay provide a means for
diagnosing emphysema at an earlier stage, even before
abnormalities develop that are detectable on pulmo-
nary function testing. Whether the detection of emphy-
sema in such early stages will have an impact on
outcomes or on the natural history of the disease by
earlier interventions is a question that should be ex-
plored in future studies. As an example, this informa-
tion could be used to identify individuals who may
need more-aggressive smoking cessation interven-
tions. Smoking cessation has been shown to reduce
the risk of lung cancer as well as to reduce the rate
of progression of COPD.25,26
Several mechanisms have been proposed to ex-
plain the link between lung cancer and COPD.27
Firstly, both diseases share tobacco smoking as the
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most important etiologic factor. However, the
majority of smokers remain disease-free through-
out their lives, and only a few have airway obstruc-
tion, emphysema, and/or lung cancer. Smoke
contains high concentrations of reactive oxygen
species together with thousands of particles that
are potentially carcinogenic and may induce in-
flammation in all smokers.28 However, it remains
unclear why there are different responses to to-
bacco with some individuals having the hallmarks
of cancer (uncontrolled cell proliferation, lack of
cellular apoptosis, tissue invasion, and angiogene-
sis), others the hallmarks of COPD (increased
apoptosis, matrix degeneration, ineffective tissue
repair, inflammation, and lack of angiogenesis),
while the majority remain disease free.27
A limitation of this study is the relatively small
number of cancers diagnosed among the study partic-
ipants. This is expected given the prospective design
and the relatively low incidence of lung cancer even
among high-risk smokers. However, the number of
cases and the prevalence of emphysema and airway
obstruction in the study population were sufficiently
large to obtain positive findings even after using strat-
ified analysis. Another potential limitation is that em-
physema on LDCT was only determined qualitatively.
However, it has been shown that qualitative assessment
is a valid and reliable tool for the characterization of
emphysema on CT.6 Furthermore, the prevalence of
emphysema based on qualitative measurements in this
study population is similar to what has been reported in
other series of high-risk individuals.29 Lastly, we lacked
complete information about current smoking status of
some study participants. Thus, we were not able to
adjust for the potential influence of smoking status
(current vs former) on the risk of lung cancer in the
multivariate analyses.
In summary, the results of this study suggest that
emphysema detected on LDCT is an independent
risk factor for lung cancer. If confirmed, this infor-
mation can be used to select candidates for lung
cancer screening or chemoprevention trials.
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